Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Biovica International publ : DiviTum - Strong prognostic marker in operable breast cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
11/20/2019 | 02:21am EST

Uppsala, Sweden, November 20, 2019. Biovica, active in cancer biomarkers, today announced clinical data that demonstrate DiviTum as a strong prognostic marker in operable breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium, SABCS, December 10-14, 2019, the world's largest scientific congress focusing on breast cancer.

The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery.

After five years, patients with low pre-operative DiviTum values (the lowest quartile, <25 percent) showed a disease-free survival rate of 81 percent versus 58 percent in the group with the highest DiviTum values (>75 percent).

"We are thrilled to see these new, interesting results. It demonstrates that pre-operative DiviTum values measured in serum is a strong prognostic marker in operable breast cancer with a potential to identify patients with the most aggressive tumors in order to personalize their therapy," said lead investigator Dr. Luca Malorni, Prato Hospital, Italy.

DiviTum measures thymidine kinase activity (TKa), an established marker of cancer cell proliferation, but until now there has been limited data regarding the role of TKa as a prognostic biomarker in operable breast cancer.

"Dr Malorni's research group has managed to show prognostic effect in a large cohort of women with operable breast cancer. This gives us high expectations on DiviTum's potential beyond monitoring of treatment for patients with metastatic breast cancer, which is our first application for DiviTum." said Anders Rylander, CEO of Biovica.

The title of the poster (P5-06-11) at San Antonio Breast Cancer Symposium is Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR+) operable breast cancer (BC).

For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

Biovica - Best Treatment from Day One.
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.




(c) 2019 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
01/16BIOVICA INTERNATIONAL PUBL : Clinical Cancer Research publishes results supporti..
2019BIOVICA INTERNATIONAL PUBL : strengthens management team
2019Q2 INTERIM REPORT : Work with the FDA application progressing as planned
2019Q2 INTERIM REPORT :  Work with the FDA application progressing as planned
2019BIOVICA INTERNATIONAL PUBL : DiviTum validated as a dynamic biomarker in metasta..
2019BIOVICA INTERNATIONAL PUBL : DiviTum - Strong prognostic marker in operable brea..
2019BIOVICA INTERNATIONAL PUBL : DiviTum validated as a dynamic biomarker in metasta..
2019BIOVICA INTERNATIONAL PUBL : strengthens with new R&D Director
2019BIOVICA ISO 13485 : 2016 certificate renewal
2019BIOVICA INTERNATIONAL PUBL : will present at the Biomarkers & Precision Medicine..
More news
Financials (SEK)
Sales 2020 4,60 M
EBIT 2020 -29,0 M
Net income 2020 -36,0 M
Finance 2020 26,0 M
Yield 2020 -
P/E ratio 2020 -11,6x
P/E ratio 2021 -81,1x
EV / Sales2020 85,8x
EV / Sales2021 19,0x
Capitalization 421 M
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Mean consensus -
Number of Analysts 2
Average target price 23,10  SEK
Last Close Price 17,85  SEK
Spread / Highest target 29,4%
Spread / Average Target 29,4%
Spread / Lowest Target 29,4%
EPS Revisions
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving Chief Financial Officer
Karin Mattsson Director-Research & Development
Sector and Competitors